6 O
ADVERSE O
REACTIONS O
The O
following O
is O
discussed O
in O
more O
detail O
in O
other O
sections O
of O
the O
labeling O
: O
* O
Seizure B-OSE_Labeled_AE
[ O
see O
Warnings O
and O
Precautions O
( O
5.1 O
) O
] O
* O
Posterior B-OSE_Labeled_AE
Reversible I-OSE_Labeled_AE
Encephalopathy I-OSE_Labeled_AE
Syndrome I-OSE_Labeled_AE
( I-OSE_Labeled_AE
PRES I-OSE_Labeled_AE
) O
[ O
see O
Warnings O
and O
Precautions O
( O
5.2 O
) O
] O
EXCERPT O
: O
The O
most O
common O
adverse O
reactions O
( O
> O
= O
10 O
% O
) O
are O
asthenia/fatigue O
, O
back O
pain O
, O
decreased O
appetite O
, O
constipation O
, O
arthralgia O
, O
diarrhea O
, O
hot O
flush O
, O
upper O
respiratory O
tract O
infection O
, O
peripheral O
edema O
, O
dyspnea O
, O
musculoskeletal O
pain O
, O
weight O
decreased O
, O
headache O
, O
hypertension O
, O
and O
dizziness/vertigo O
. O

( O
6.1 O
) O
To O
report O
SUSPECTED O
ADVERSE O
REACTIONS O
, O
contact O
Astellas O
Pharma O
US O
, O
Inc O
. O
at O
1-800-727-7003 O
or O
FDA O
at O
1-800-FDA-1088 O
or O
www.fda.gov/medwatch O
. O

6.1 O
Clinical O
Trial O
Experience O
Because O
clinical O
trials O
are O
conducted O
under O
widely O
varying O
conditions O
, O
adverse O
reaction O
rates O
observed O
in O
the O
clinical O
trials O
of O
a O
drug O
can O
not O
be O
directly O
compared O
to O
rates O
in O
the O
clinical O
trials O
of O
another O
drug O
and O
may O
not O
reflect O
the O
rates O
observed O
in O
practice O
. O

Three O
randomized O
clinical O
trials O
enrolled O
patients O
with O
metastatic B-Not_AE_Candidate
prostate I-Not_AE_Candidate
cancer I-Not_AE_Candidate
that O
has O
progressed O
on O
androgen O
deprivation O
therapy O
( O
GnRH O
therapy O
or O
bilateral O
orchiectomy O
) O
, O
a O
disease O
setting O
that O
is O
also O
defined O
as O
metastatic B-Not_AE_Candidate
CRPC I-Not_AE_Candidate
. O

Two O
trials O
were O
placebo-controlled O
( O
Studies O
1 O
and O
2 O
) O
, O
and O
one O
trial O
was O
bicalutamide-controlled O
( O
Study O
3 O
) O
. O

In O
Studies O
1 O
and O
2 O
, O
patients O
received O
XTANDI O
160 O
mg O
or O
placebo O
orally O
once O
daily O
. O

In O
Study O
3 O
, O
patients O
received O
XTANDI O
160 O
mg O
or O
bicalutamide O
50 O
mg O
orally O
once O
daily O
. O

All O
patients O
continued O
androgen O
deprivation O
therapy O
. O

Patients O
were O
allowed O
, O
but O
not O
required O
, O
to O
take O
glucocorticoids O
. O

The O
most O
common O
adverse O
reactions O
( O
> O
= O
10 O
% O
) O
that O
occurred O
more O
commonly O
( O
> O
= O
2 O
% O
over O
placebo O
) O
in O
the O
XTANDI-treated O
patients O
from O
the O
two O
randomized O
placebo-controlled O
clinical O
trials O
were O
asthenia B-OSE_Labeled_AE
/ O
fatigue B-OSE_Labeled_AE
, O
back B-OSE_Labeled_AE
pain I-OSE_Labeled_AE
, O
decreased B-OSE_Labeled_AE
appetite I-OSE_Labeled_AE
, O
constipation B-OSE_Labeled_AE
, O
arthralgia B-OSE_Labeled_AE
, O
diarrhea B-OSE_Labeled_AE
, O
hot B-OSE_Labeled_AE
flush I-OSE_Labeled_AE
, O
upper B-OSE_Labeled_AE
respiratory I-OSE_Labeled_AE
tract I-OSE_Labeled_AE
infection I-OSE_Labeled_AE
, O
peripheral B-OSE_Labeled_AE
edema I-OSE_Labeled_AE
, O
dyspnea B-OSE_Labeled_AE
, O
musculoskeletal B-OSE_Labeled_AE
pain I-OSE_Labeled_AE
, O
weight B-OSE_Labeled_AE
decreased I-OSE_Labeled_AE
, O
headache B-OSE_Labeled_AE
, O
hypertension B-OSE_Labeled_AE
, O
and O
dizziness B-OSE_Labeled_AE
/ O
vertigo B-OSE_Labeled_AE
. O

Study O
1 O
: O
XTANDI O
versus O
Placebo O
in O
Metastatic O
CRPC O
Following O
Chemotherapy O
Study O
1 O
enrolled O
1199 O
patients O
with O
metastatic B-Not_AE_Candidate
CRPC I-Not_AE_Candidate
who O
had O
previously O
received O
docetaxel O
. O

The O
median O
duration O
of O
treatment O
was O
8.3 O
months O
with O
XTANDI O
and O
3.0 O
months O
with O
placebo O
. O

During O
the O
trial O
, O
48 O
% O
of O
patients O
on O
the O
XTANDI O
arm O
and O
46 O
% O
of O
patients O
on O
the O
placebo O
arm O
received O
glucocorticoids O
. O

Grade O
3 O
and O
higher O
adverse O
reactions O
were O
reported O
among O
47 O
% O
of O
XTANDI-treated O
patients O
and O
53 O
% O
of O
placebo-treated O
patients O
. O

Discontinuations O
due O
to O
adverse O
events O
were O
reported O
for O
16 O
% O
of O
XTANDI-treated O
patients O
and O
18 O
% O
of O
placebo-treated O
patients O
. O

The O
most O
common O
adverse O
reaction O
leading O
to O
treatment O
discontinuation O
was O
seizure B-OSE_Labeled_AE
, O
which O
occurred O
in O
0.9 O
% O
of O
the O
XTANDI-treated O
patients O
compared O
to O
none O
( O
0 O
% O
) O
of O
the O
placebo-treated O
patients O
. O

Table O
1 O
shows O
adverse O
reactions O
reported O
in O
Study O
1 O
that O
occurred O
at O
a O
> O
= O
2 O
% O
higher O
frequency O
in O
the O
XTANDI O
arm O
compared O
to O
the O
placebo O
arm O
. O

Table O
1 O
. O

Adverse O
Reactions O
in O
Study O
1 O
XTANDI O
N O
= O
800 O
Placebo O
N O
= O
399 O
Grade O
1-4a O
( O
% O
) O
Grade O
3-4 O
( O
% O
) O
Grade O
1-4 O
( O
% O
) O
Grade O
3-4 O
( O
% O
) O
General B-NonOSE_AE
Disorders I-NonOSE_AE
Asthenic B-OSE_Labeled_AE
Conditions I-OSE_Labeled_AE
b O
50.6 O
9.0 O
44.4 O
9.3 O
Peripheral B-OSE_Labeled_AE
Edema I-OSE_Labeled_AE
15.4 O
1.0 O
13.3 O
0.8 O
Musculoskeletal B-NonOSE_AE
And I-NonOSE_AE
Connective I-NonOSE_AE
Tissue I-NonOSE_AE
Disorders I-NonOSE_AE
Back B-OSE_Labeled_AE
Pain I-OSE_Labeled_AE
26.4 O
5.3 O
24.3 O
4.0 O
Arthralgia B-OSE_Labeled_AE
20.5 O
2.5 O
17.3 O
1.8 O
Musculoskeletal B-OSE_Labeled_AE
Pain I-OSE_Labeled_AE
15.0 O
1.3 O
11.5 O
0.3 O
Muscular B-OSE_Labeled_AE
Weakness I-OSE_Labeled_AE
9.8 O
1.5 O
6.8 O
1.8 O
Musculoskeletal B-OSE_Labeled_AE
Stiffness I-OSE_Labeled_AE
2.6 O
0.3 O
0.3 O
0.0 O
Gastrointestinal B-NonOSE_AE
Disorders I-NonOSE_AE
Diarrhea B-OSE_Labeled_AE
21.8 O
1.1 O
17.5 O
0.3 O
Vascular B-NonOSE_AE
Disorders I-NonOSE_AE
Hot B-OSE_Labeled_AE
Flush I-OSE_Labeled_AE
20.3 O
0.0 O
10.3 O
0.0 O
Hypertension B-OSE_Labeled_AE
6.4 O
2.1 O
2.8 O
1.3 O
Nervous B-NonOSE_AE
System I-NonOSE_AE
Disorders I-NonOSE_AE
Headache B-OSE_Labeled_AE
12.1 O
0.9 O
5.5 O
0.0 O
Dizziness B-OSE_Labeled_AE
c O
9.5 O
0.5 O
7.5 O
0.5 O
Spinal B-OSE_Labeled_AE
Cord I-OSE_Labeled_AE
Compression I-OSE_Labeled_AE
and O
Cauda B-OSE_Labeled_AE
Equina I-OSE_Labeled_AE
Syndrome I-OSE_Labeled_AE
7.4 O
6.6 O
4.5 O
3.8 O
Paresthesia B-OSE_Labeled_AE
6.6 O
0.0 O
4.5 O
0.0 O
Mental B-OSE_Labeled_AE
Impairment I-OSE_Labeled_AE
Disordersd I-OSE_Labeled_AE
4.3 O
0.3 O
1.8 O
0.0 O
Hypoesthesia B-OSE_Labeled_AE
4.0 O
0.3 O
1.8 O
0.0 O
Infections B-NonOSE_AE
And I-NonOSE_AE
Infestations I-NonOSE_AE
Upper B-OSE_Labeled_AE
Respiratory I-OSE_Labeled_AE
Tract I-OSE_Labeled_AE
Infection I-OSE_Labeled_AE
e O
10.9 O
0.0 O
6.5 O
0.3 O
Lower B-OSE_Labeled_AE
Respiratory I-OSE_Labeled_AE
Tract I-OSE_Labeled_AE
And O
Lung O
Infection I-OSE_Labeled_AE
f O
8.5 O
2.4 O
4.8 O
1.3 O
Psychiatric B-NonOSE_AE
Disorders I-NonOSE_AE
Insomnia B-OSE_Labeled_AE
8.8 O
0.0 O
6.0 O
0.5 O
Anxiety B-OSE_Labeled_AE
6.5 O
0.3 O
4.0 O
0.0 O
Renal B-NonOSE_AE
And I-NonOSE_AE
Urinary I-NonOSE_AE
Disorders I-NonOSE_AE
Hematuria B-OSE_Labeled_AE
6.9 O
1.8 O
4.5 O
1.0 O
Pollakiuria B-OSE_Labeled_AE
4.8 O
0.0 O
2.5 O
0.0 O
Injury B-NonOSE_AE
, I-NonOSE_AE
Poisoning I-NonOSE_AE
And I-NonOSE_AE
Procedural I-NonOSE_AE
Complications I-NonOSE_AE
Fall B-OSE_Labeled_AE
4.6 O
0.3 O
1.3 O
0.0 O
Non B-OSE_Labeled_AE
- I-OSE_Labeled_AE
pathologic I-OSE_Labeled_AE
Fractures I-OSE_Labeled_AE
4.0 O
1.4 O
0.8 O
0.3 O
Skin B-NonOSE_AE
And I-NonOSE_AE
Subcutaneous I-NonOSE_AE
Tissue I-NonOSE_AE
Disorders I-NonOSE_AE
Pruritus B-OSE_Labeled_AE
3.8 O
0.0 O
1.3 O
0.0 O
Dry B-OSE_Labeled_AE
Skin I-OSE_Labeled_AE
3.5 O
0.0 O
1.3 O
0.0 O
Respiratory B-NonOSE_AE
Disorders I-NonOSE_AE
Epistaxis B-OSE_Labeled_AE
3.3 O
0.1 O
1.3 O
0.3 O
a O
CTCAE O
v4 O
b O
Includes O
asthenia B-OSE_Labeled_AE
and O
fatigue B-OSE_Labeled_AE
. O

c O
Includes O
dizziness B-OSE_Labeled_AE
and O
vertigo B-OSE_Labeled_AE
. O

d O
Includes O
amnesia B-OSE_Labeled_AE
, O
memory B-OSE_Labeled_AE
impairment I-OSE_Labeled_AE
, O
cognitive B-OSE_Labeled_AE
disorder I-OSE_Labeled_AE
, O
and O
disturbance B-OSE_Labeled_AE
in I-OSE_Labeled_AE
attention I-OSE_Labeled_AE
. O

e O
Includes O
nasopharyngitis B-OSE_Labeled_AE
, O
upper B-OSE_Labeled_AE
respiratory I-OSE_Labeled_AE
tract I-OSE_Labeled_AE
infection I-OSE_Labeled_AE
, O
sinusitis B-OSE_Labeled_AE
, O
rhinitis B-OSE_Labeled_AE
, O
pharyngitis B-OSE_Labeled_AE
, O
and O
laryngitis B-OSE_Labeled_AE
. O

f O
Includes O
pneumonia B-OSE_Labeled_AE
, O
lower B-OSE_Labeled_AE
respiratory I-OSE_Labeled_AE
tract I-OSE_Labeled_AE
infection I-OSE_Labeled_AE
, O
bronchitis B-OSE_Labeled_AE
, O
and O
lung B-OSE_Labeled_AE
infection I-OSE_Labeled_AE
. O

Study O
2 O
: O
XTANDI O
versus O
Placebo O
in O
Chemotherapy-naive O
Metastatic O
CRPC O
Study O
2 O
enrolled O
1717 O
patients O
with O
metastatic B-Not_AE_Candidate
CRPC I-Not_AE_Candidate
who O
had O
not O
received O
prior O
cytotoxic B-NonOSE_AE
chemotherapy I-NonOSE_AE
, O
of O
whom O
1715 O
received O
at O
least O
one O
dose O
of O
study O
drug O
. O

The O
median O
duration O
of O
treatment O
was O
17.5 O
months O
with O
XTANDI O
and O
4.6 O
months O
with O
placebo O
. O

Grade O
3-4 O
adverse O
reactions O
were O
reported O
in O
44 O
% O
of O
XTANDI-treated O
patients O
and O
37 O
% O
of O
placebo-treated O
patients O
. O

Discontinuations O
due O
to O
adverse O
events O
were O
reported O
for O
6 O
% O
of O
XTANDI-treated O
patients O
and O
6 O
% O
of O
placebo-treated O
patients O
. O

The O
most O
common O
adverse O
reaction O
leading O
to O
treatment O
discontinuation O
was O
fatigue B-OSE_Labeled_AE
/ O
asthenia B-OSE_Labeled_AE
, O
which O
occurred O
in O
1 O
% O
of O
patients O
on O
each O
treatment O
arm O
. O

Table O
2 O
includes O
adverse O
reactions O
reported O
in O
Study O
2 O
that O
occurred O
at O
a O
> O
= O
2 O
% O
higher O
frequency O
in O
the O
XTANDI O
arm O
compared O
to O
the O
placebo O
arm O
. O

Table O
2 O
. O

Adverse O
Reactions O
in O
Study O
2 O
XTANDI O
N O
= O
871 O
Placebo O
N O
= O
844 O
Grade O
1-4 O
a O
( O
% O
) O
Grade O
3-4 O
( O
% O
) O
Grade O
1-4 O
( O
% O
) O
Grade O
3-4 O
( O
% O
) O
General B-NonOSE_AE
Disorders I-NonOSE_AE
Asthenic B-OSE_Labeled_AE
Conditions I-OSE_Labeled_AE
b O
46.9 O
3.4 O
33.0 O
2.8 O
Peripheral B-OSE_Labeled_AE
Edema I-OSE_Labeled_AE
11.5 O
0.2 O
8.2 O
0.4 O
Musculoskeletal B-NonOSE_AE
And I-NonOSE_AE
Connective I-NonOSE_AE
Tissue I-NonOSE_AE
Disorders I-NonOSE_AE
Back B-OSE_Labeled_AE
Pain I-OSE_Labeled_AE
28.6 O
2.5 O
22.4 O
3.0 O
Arthralgia B-OSE_Labeled_AE
21.4 O
1.6 O
16.1 O
1.1 O
Gastrointestinal B-NonOSE_AE
Disorders I-NonOSE_AE
Constipation B-OSE_Labeled_AE
23.2 O
0.7 O
17.3 O
0.4 O
Diarrhea B-OSE_Labeled_AE
16.8 O
0.3 O
14.3 O
0.4 O
Vascular B-NonOSE_AE
Disorders I-NonOSE_AE
Hot B-OSE_Labeled_AE
Flush I-OSE_Labeled_AE
18.0 O
0.1 O
7.8 O
0.0 O
Hypertension B-OSE_Labeled_AE
14.2 O
7.2 O
4.1 O
2.3 O
Nervous B-NonOSE_AE
System I-NonOSE_AE
Disorders I-NonOSE_AE
Dizziness B-OSE_Labeled_AE
c O
11.3 O
0.3 O
7.1 O
0.0 O
Headache B-OSE_Labeled_AE
11.0 O
0.2 O
7.0 O
0.4 O
Dysgeusia B-OSE_Labeled_AE
7.6 O
0.1 O
3.7 O
0.0 O
Mental B-OSE_Labeled_AE
Impairment I-OSE_Labeled_AE
Disordersd I-OSE_Labeled_AE
5.7 O
0.0 O
1.3 O
0.1 O
Restless B-OSE_Labeled_AE
Legs I-OSE_Labeled_AE
Syndrome I-OSE_Labeled_AE
2.1 O
0.1 O
0.4 O
0.0 O
Respiratory B-NonOSE_AE
Disorders I-NonOSE_AE
Dyspneae B-OSE_Labeled_AE
11.0 O
0.6 O
8.5 O
0.6 O
Infections B-NonOSE_AE
And I-NonOSE_AE
Infestations I-NonOSE_AE
Upper B-OSE_Labeled_AE
Respiratory I-OSE_Labeled_AE
Tract I-OSE_Labeled_AE
Infection I-OSE_Labeled_AE
f O
16.4 O
0.0 O
10.5 O
0.0 O
Lower B-OSE_Labeled_AE
Respiratory I-OSE_Labeled_AE
Tract I-OSE_Labeled_AE
And O
Lung O
Infection I-OSE_Labeled_AE
g O
7.9 O
1.5 O
4.7 O
1.1 O
Psychiatric B-NonOSE_AE
Disorders I-NonOSE_AE
Insomnia B-OSE_Labeled_AE
8.2 O
0.1 O
5.7 O
0.0 O
Renal B-NonOSE_AE
And I-NonOSE_AE
Urinary I-NonOSE_AE
Disorders I-NonOSE_AE
Hematuria B-OSE_Labeled_AE
8.8 O
1.3 O
5.8 O
1.3 O
Injury B-NonOSE_AE
, I-NonOSE_AE
Poisoning I-NonOSE_AE
And I-NonOSE_AE
Procedural I-NonOSE_AE
Complications I-NonOSE_AE
Fall B-OSE_Labeled_AE
12.7 O
1.6 O
5.3 O
0.7 O
Non B-OSE_Labeled_AE
- I-OSE_Labeled_AE
Pathological I-OSE_Labeled_AE
Fracture I-OSE_Labeled_AE
8.8 O
2.1 O
3.0 O
1.1 O
Metabolism B-NonOSE_AE
and I-NonOSE_AE
Nutrition I-NonOSE_AE
Disorders I-NonOSE_AE
Decreased B-OSE_Labeled_AE
Appetite I-OSE_Labeled_AE
18.9 O
0.3 O
16.4 O
0.7 O
Investigations B-NonOSE_AE
Weight B-OSE_Labeled_AE
Decreased I-OSE_Labeled_AE
12.4 O
0.8 O
8.5 O
0.2 O
Reproductive B-NonOSE_AE
System I-NonOSE_AE
and I-NonOSE_AE
Breast I-NonOSE_AE
disorders I-NonOSE_AE
Gynecomastia B-OSE_Labeled_AE
3.4 O
0.0 O
1.4 O
0.0 O
a O
CTCAE O
v4 O
b O
Includes O
asthenia B-OSE_Labeled_AE
and O
fatigue B-OSE_Labeled_AE
. O

c O
Includes O
dizziness B-OSE_Labeled_AE
and O
vertigo B-OSE_Labeled_AE
. O

d O
Includes O
amnesia B-OSE_Labeled_AE
, O
memory B-OSE_Labeled_AE
impairment I-OSE_Labeled_AE
, O
cognitive B-OSE_Labeled_AE
disorder I-OSE_Labeled_AE
, O
and O
disturbance B-OSE_Labeled_AE
in I-OSE_Labeled_AE
attention I-OSE_Labeled_AE
. O

e O
Includes O
dyspnea B-OSE_Labeled_AE
, O
exertional B-OSE_Labeled_AE
dyspnea I-OSE_Labeled_AE
, O
and O
dyspnea B-OSE_Labeled_AE
at I-OSE_Labeled_AE
rest I-OSE_Labeled_AE
. O

f O
Includes O
nasopharyngitis B-OSE_Labeled_AE
, O
upper B-OSE_Labeled_AE
respiratory I-OSE_Labeled_AE
tract I-OSE_Labeled_AE
infection I-OSE_Labeled_AE
, O
sinusitis B-OSE_Labeled_AE
, O
rhinitis B-OSE_Labeled_AE
, O
pharyngitis B-OSE_Labeled_AE
, O
and O
laryngitis B-OSE_Labeled_AE
. O

g O
Includes O
pneumonia B-OSE_Labeled_AE
, O
lower B-OSE_Labeled_AE
respiratory I-OSE_Labeled_AE
tract I-OSE_Labeled_AE
infection I-OSE_Labeled_AE
, O
bronchitis B-OSE_Labeled_AE
, O
and O
lung B-OSE_Labeled_AE
infection I-OSE_Labeled_AE
. O

Study O
3 O
: O
XTANDI O
versus O
Bicalutamide O
in O
Chemotherapy-naive O
Metastatic O
CRPC O
Study O
3 O
enrolled O
375 O
patients O
with O
metastatic B-Not_AE_Candidate
CRPC I-Not_AE_Candidate
who O
had O
not O
received O
prior O
cytotoxic B-NonOSE_AE
chemotherapy I-NonOSE_AE
, O
of O
whom O
372 O
received O
at O
least O
one O
dose O
of O
study O
drug O
. O

The O
median O
duration O
of O
treatment O
was O
11.6 O
months O
with O
XTANDI O
and O
5.8 O
months O
with O
bicalutamide O
. O

Discontinuations O
with O
an O
adverse O
event O
as O
the O
primary O
reason O
were O
reported O
for O
7.6 O
% O
of O
XTANDI-treated O
patients O
and O
6.3 O
% O
of O
bicalutamide-treated O
patients O
. O

The O
most O
common O
adverse O
reactions O
leading O
to O
treatment O
discontinuation O
were O
back B-OSE_Labeled_AE
pain I-OSE_Labeled_AE
and O
pathological B-OSE_Labeled_AE
fracture I-OSE_Labeled_AE
, O
which O
occurred O
in O
3.8 O
% O
of O
XTANDI-treated O
patients O
for O
each O
event O
and O
in O
2.1 O
% O
and O
1.6 O
% O
of O
bicalutamide-treated O
patients O
, O
respectively O
. O

Table O
3 O
shows O
overall O
and O
common O
adverse O
reactions O
( O
> O
= O
10 O
% O
) O
in O
XTANDI-treated O
patients O
. O

Table O
3 O
. O

Adverse O
Reactions O
in O
Study O
3 O
XTANDI O
( O
N=183 O
) O
Bicalutamide O
( O
N=189 O
) O
Grade O
1-4 O
a O
( O
% O
) O
Grade O
3-4 O
( O
% O
) O
Grade O
1-4 O
a O
( O
% O
) O
Grade O
3-4 O
( O
% O
) O
Overall O
94.0 O
38.8 O
94.2 O
37.6 O
General B-NonOSE_AE
Disorders I-NonOSE_AE
Asthenic B-OSE_Labeled_AE
Conditions I-OSE_Labeled_AE
b O
31.7 O
1.6 O
22.8 O
1.1 O
Musculoskeletal B-NonOSE_AE
And I-NonOSE_AE
Connective I-NonOSE_AE
Tissue I-NonOSE_AE
Disorders I-NonOSE_AE
Back B-OSE_Labeled_AE
Pain I-OSE_Labeled_AE
19.1 O
2.7 O
18.0 O
1.6 O
Musculoskeletal B-OSE_Labeled_AE
Pain I-OSE_Labeled_AE
c O
16.4 O
1.1 O
14.3 O
0.5 O
Vascular B-NonOSE_AE
Disorders I-NonOSE_AE
Hot B-OSE_Labeled_AE
Flush I-OSE_Labeled_AE
14.8 O
0 O
11.1 O
0 O
Hypertension B-OSE_Labeled_AE
14.2 O
7.1 O
7.4 O
4.2 O
Gastrointestinal B-NonOSE_AE
Disorders I-NonOSE_AE
Nausea B-OSE_Labeled_AE
14.2 O
0 O
17.5 O
0 O
Constipation B-OSE_Labeled_AE
12.6 O
1.1 O
13.2 O
0.5 O
Diarrhea B-OSE_Labeled_AE
11.5 O
0 O
9.0 O
1.1 O
Infections B-NonOSE_AE
And I-NonOSE_AE
Infestations I-NonOSE_AE
Upper B-OSE_Labeled_AE
Respiratory I-OSE_Labeled_AE
Tract I-OSE_Labeled_AE
Infection I-OSE_Labeled_AE
d O
12.0 O
0 O
6.3 O
0.5 O
Investigational B-NonOSE_AE
Weight B-OSE_Labeled_AE
Loss I-OSE_Labeled_AE
10.9 O
0.5 O
7.9 O
0.5 O
a O
CTCAE O
v O
4b O
Including O
asthenia B-OSE_Labeled_AE
and O
fatigue B-OSE_Labeled_AE
.c O
Including O
musculoskeletal B-OSE_Labeled_AE
pain I-OSE_Labeled_AE
and O
pain B-OSE_Labeled_AE
in I-OSE_Labeled_AE
extremity I-OSE_Labeled_AE
d O
Including O
nasopharyngitis B-OSE_Labeled_AE
, O
upper B-OSE_Labeled_AE
respiratory I-OSE_Labeled_AE
tract I-OSE_Labeled_AE
infection I-OSE_Labeled_AE
, O
sinusitis B-OSE_Labeled_AE
, O
rhinitis B-OSE_Labeled_AE
, O
pharyngitis B-OSE_Labeled_AE
, O
and O
laryngitis B-OSE_Labeled_AE
Laboratory O
Abnormalities O
In O
the O
two O
randomized O
placebo-controlled O
clinical O
trials O
, O
Grade O
1-4 O
neutropenia B-OSE_Labeled_AE
occurred O
in O
15 O
% O
of O
patients O
treated O
with O
XTANDI O
( O
1 O
% O
Grade O
3-4 O
) O
and O
in O
6 O
% O
of O
patients O
treated O
with O
placebo O
( O
0.5 O
% O
Grade O
3-4 O
) O
. O

The O
incidence O
of O
Grade O
1-4 O
thrombocytopenia B-OSE_Labeled_AE
was O
6 O
% O
of O
patients O
treated O
with O
XTANDI O
( O
0.3 O
% O
Grade O
3-4 O
) O
and O
5 O
% O
of O
patients O
treated O
with O
placebo O
( O
0.5 O
% O
Grade O
3-4 O
) O
. O

Grade O
1-4 O
elevations B-NonOSE_AE
in I-NonOSE_AE
ALT I-NonOSE_AE
occurred O
in O
10 O
% O
of O
patients O
treated O
with O
XTANDI O
( O
0.2 O
% O
Grade O
3-4 O
) O
and O
16 O
% O
of O
patients O
treated O
with O
placebo O
( O
0.2 O
% O
Grade O
3-4 O
) O
. O

Grade O
1-4 O
elevations B-OSE_Labeled_AE
in I-OSE_Labeled_AE
bilirubin I-OSE_Labeled_AE
occurred O
in O
3 O
% O
of O
patients O
treated O
with O
XTANDI O
( O
0.1 O
% O
Grade O
3-4 O
) O
and O
2 O
% O
of O
patients O
treated O
with O
placebo O
( O
no O
Grade O
3-4 O
) O
. O

Infections O
In O
Study O
1 O
, O
1 O
% O
of O
patients O
treated O
with O
XTANDI O
compared O
to O
0.3 O
% O
of O
patients O
treated O
with O
placebo O
died B-NonOSE_AE
from O
infections B-NonOSE_AE
or O
sepsis B-NonOSE_AE
. O

In O
Study O
2 O
, O
1 O
patient O
in O
each O
treatment O
group O
( O
0.1 O
% O
) O
had O
an O
infection B-NonOSE_AE
resulting O
in O
death B-NonOSE_AE
. O

Falls O
and O
Fall-related O
Injuries O
In O
the O
two O
randomized O
placebo-controlled O
clinical O
trials O
, O
falls B-OSE_Labeled_AE
including O
fall B-OSE_Labeled_AE
- I-OSE_Labeled_AE
related I-OSE_Labeled_AE
injuries I-OSE_Labeled_AE
, O
occurred O
in O
9 O
% O
of O
patients O
treated O
with O
XTANDI O
compared O
to O
4 O
% O
of O
patients O
treated O
with O
placebo O
. O

Falls B-NonOSE_AE
were O
not O
associated O
with O
loss B-NonOSE_AE
of I-NonOSE_AE
consciousness I-NonOSE_AE
or O
seizure B-NonOSE_AE
. O

Fall B-OSE_Labeled_AE
- I-OSE_Labeled_AE
related I-OSE_Labeled_AE
injuries I-OSE_Labeled_AE
were O
more O
severe O
in O
patients O
treated O
with O
XTANDI O
and O
included O
non-pathologic O
fractures O
, O
joint O
injuries O
, O
and O
hematomas O
. O

Hypertension O
In O
the O
two O
randomized O
placebo-controlled O
trials O
, O
hypertension B-OSE_Labeled_AE
was O
reported O
in O
11 O
% O
of O
patients O
receiving O
XTANDI O
and O
4 O
% O
of O
patients O
receiving O
placebo O
. O

No O
patients O
experienced O
hypertensive B-NonOSE_AE
crisis I-NonOSE_AE
. O

Medical O
history O
of O
hypertension B-Not_AE_Candidate
was O
balanced O
between O
arms O
. O

Hypertension B-OSE_Labeled_AE
led O
to O
study O
discontinuation O
in O
< O
1 O
% O
of O
patients O
in O
each O
arm O
. O

6.2 O
Post-Marketing O
Experience O
The O
following O
additional O
adverse O
reactions O
have O
been O
identified O
during O
post O
approval O
use O
of O
XTANDI O
. O

Because O
these O
reactions O
were O
reported O
voluntarily O
from O
a O
population O
of O
uncertain O
size O
, O
it O
is O
not O
always O
possible O
to O
reliably O
estimate O
the O
frequency O
or O
establish O
a O
causal O
relationship O
to O
drug O
exposure O
. O

Body B-NonOSE_AE
as I-NonOSE_AE
a I-NonOSE_AE
Whole I-NonOSE_AE
: O
hypersensitivity B-OSE_Labeled_AE
( O
tongue B-OSE_Labeled_AE
edema I-OSE_Labeled_AE
, O
lip B-OSE_Labeled_AE
edema I-OSE_Labeled_AE
, O
and O
pharyngeal B-OSE_Labeled_AE
edema I-OSE_Labeled_AE
) O
Gastrointestinal B-NonOSE_AE
Disorders I-NonOSE_AE
: O
vomiting B-OSE_Labeled_AE
Neurological B-NonOSE_AE
Disorders I-NonOSE_AE
: O
posterior B-OSE_Labeled_AE
reversible I-OSE_Labeled_AE
encephalopathy I-OSE_Labeled_AE
syndrome I-OSE_Labeled_AE
( I-OSE_Labeled_AE
PRES I-OSE_Labeled_AE
) O
Skin B-NonOSE_AE
and I-NonOSE_AE
Subcutaneous I-NonOSE_AE
Tissue I-NonOSE_AE
Disorders I-NonOSE_AE
: O
rash B-OSE_Labeled_AE

